582 related articles for article (PubMed ID: 30337059)
21. MSH2 Loss in Primary Prostate Cancer.
Guedes LB; Antonarakis ES; Schweizer MT; Mirkheshti N; Almutairi F; Park JC; Glavaris S; Hicks J; Eisenberger MA; De Marzo AM; Epstein JI; Isaacs WB; Eshleman JR; Pritchard CC; Lotan TL
Clin Cancer Res; 2017 Nov; 23(22):6863-6874. PubMed ID: 28790115
[No Abstract] [Full Text] [Related]
22. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
23. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
[TBL] [Abstract][Full Text] [Related]
24. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
26. Defects of DNA mismatch repair in human prostate cancer.
Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS
Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301
[TBL] [Abstract][Full Text] [Related]
28. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
29. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Lotan TL; Kaur HB; Alharbi AM; Pritchard CC; Epstein JI
Histopathology; 2019 May; 74(6):836-843. PubMed ID: 30636012
[TBL] [Abstract][Full Text] [Related]
30. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.
Marshall CH; Fu W; Wang H; Baras AS; Lotan TL; Antonarakis ES
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):59-65. PubMed ID: 30171229
[TBL] [Abstract][Full Text] [Related]
32. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
Patel SA; Longacre TA; Ladabaum U; Lebensohn A; Lin AY; Haraldsdottir S
Oncologist; 2018 Dec; 23(12):1395-1400. PubMed ID: 30072391
[TBL] [Abstract][Full Text] [Related]
33. Current Understanding and Management of Intraductal Carcinoma of the Prostate.
Considine B; Adeniran A; Hurwitz ME
Curr Oncol Rep; 2021 Jul; 23(9):110. PubMed ID: 34272624
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
35. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
[TBL] [Abstract][Full Text] [Related]
36. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
38. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
40. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.
Basu S; Majumder S; Bhowal A; Ghosh A; Naskar S; Nandy S; Mukherjee S; Sinha RK; Basu K; Karmakar D; Banerjee S; Sengupta S
PLoS One; 2015; 10(5):e0125560. PubMed ID: 25938433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]